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Synthesis, Characterization, and Cytotoxicity of a
Series of Estrogen-Tethered Platinum(IV) Complexes
(HMG) domain proteins, such as HMGB1 [6, 9, 10]. The
binding of these proteins to platinum-DNA adducts
modulates the cytotoxicity of cisplatin [11–13] and offers
Katie R. Barnes, Alexander Kutikov,
and Stephen J. Lippard*
Department of Chemistry
Massachusetts Institute of Technology new strategies for improving the chemotherapeutic po-
tential of platinum-based anticancer drugs [14].Cambridge, Massachusetts 02139
Recent work from our laboratory revealed that estro-
gen receptor-positive, or ER(), cells treated with estro-
gen are sensitized to cisplatin [15]; estrogen inducesSummary
overexpression of HMGB1, a protein that shields cis-
platin-DNA adducts from nucleotide excision repairSeveral estrogen-tethered platinum(IV) complexes
(NER) [11, 15, 16]. This finding suggested to us thatwere prepared and characterized by ESI-MS and 1H
estrogen-tethered platinum(IV) complexes might proveNMR spectroscopy. Their design was inspired by the
valuable as novel anticancer drug candidates. The pro-observation that estrogen receptor-positive cells ex-
posed mechanism is illustrated in Figure 1. Upon enter-posed to the hormone are sensitized to cisplatin. Intra-
ing the reducing environment of the cell, the platinum(IV)cellular reduction of bis-estrogen-cis-diamminedi-
complexes will be reduced to platinum(II) and simultane-chloroplatinum(IV), BEPn (where n  1–5 methylene
ously release one equivalent of cisplatin and two equiva-groups between Pt and estrogen), occurs to afford
lents of a linker-modified estrogen. Subsequent bindingcisplatin and two equivalents of the linker-modified
of cisplatin to DNA and hydrolysis of the ester moietiesestrogen. The ability of BEPn to induce overexpression
should lead to HMGB1 upregulation, as describedof HMGB1 was established by immunofluorescence
above, as well as sensitization of the cells as a resultmicroscopy. The cytotoxicity of the compounds was
of repair shielding of the cisplatin-DNA adducts.evaluated in ER() MCF-7 and ER() HCC-1937 human
In the present article, we describe the application ofbreast cancer cell lines. BEP3 selectively induces
this strategy through the design, synthesis, and charac-overexpression of HMGB1 in MCF-7 cells, compared
terization of a series of compounds, BEP1–BEP5 (Figureto HCC-1937 cells, and enhances their sensitivity
2). In these molecules, estradiol is tethered to the termi-(IC50  2.1  0.4 M versus 3.7  0.9 M, respectively)
nal carboxylate groups of cis, cis, trans-diamminedi-to the compound. The difference in compound activi-
chlorodisuccinatoplatinum(IV) through polymethyleneties and the potential of compounds of this class for
chains of varying lengths. We programmed this variabil-treating breast and ovarian cancer are discussed.
ity into our study to allow for the best match between the
kinetics of estrogen-mediated HMGB1 overproduction
Introduction and cisplatin-DNA adduct formation in the cancer cell.
Here we report and discuss the ability of the BEPn (bis-The anticancer activity of cisplatin was discovered ser- estrogen-cis-diamminedichloroplatinum(IV) compounds
endipitously more than three decades ago [1]. Today, containing n methylene linker chain groups) complexes
cisplatin is used to treat testicular cancer, with success to upregulate HMGB1, as well as their cytotoxic profile
rates of greater than 90% [2, 3], as well as breast, ovar- in both ER() and ER() cells.
ian, bladder, lung, and head and neck carcinomas, either
alone or in combination therapy [4]. Because cisplatin
has adverse side effects, is limited to a narrow range Results and Discussion
of cancers, and can be rendered inactive due to acquired
resistance [2], research has focused on elucidating its Synthesis and Characterization of BEP1–BEP5
mechanism of action to guide the rational synthesis of The preparation of several steroid-tethered platinum
improved platinum analogs. complexes has been reported [17–21]. None of these
Cisplatin can bind to RNA, proteins, and other sulfur- compounds enables the release of unmodified estrogen
containing biomolecules, but DNA is its primary biologi- inside cells, nor are any expected to affect the expres-
cal target [5–7]. Various adducts form when cisplatin sion of HMGB1 because of their low affinity for the estro-
binds to DNA, with 1,2-intrastrand d(GpG) and d(ApG) gen receptor (ER). Previously synthesized platinum-
crosslinks accounting for approximately 90% of such estrogen conjugates were designed to take advantage
interactions [6, 8]; a smaller number of 1,3-intrastrand of known steroid transport mechanisms to accumulate
and interstrand crosslinks also form. These adducts specifically in ER() cells [17–19]. The present study
block transcription, inhibit replication, and ultimately in- describes the first report of a hormone-conjugated plati-
duce apoptosis [6]. The DNA duplex is significantly dis- num(IV) complex linked at the 17 position. We chose
torted upon formation of cisplatin 1,2-intrastrand cross- this particular strategy for several reasons. Platinum(IV)
links [9]. The resulting structure serves as a recognition complexes are relatively inert to ligand substitution,
motif for a variety of cellular proteins, including DNA which allows for oral administration and differentiates
repair components, histones, and high-mobility group their pharmacokinetic properties from those of cisplatin
[22, 23]. In addition, the designed platinum(IV) com-
plexes facilitate simultaneous delivery of cisplatin and*Correspondence: lippard@lippard.mit.edu
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Figure 1. Proposed Mechanism of Action for
Estrogen-Tethered Platinum(IV) Complexes
The reducing environment of the cell will con-
vert platinum(IV) to platinum(II) and thereby
release cisplatin and two equivalents of a
modified estrogen. Upregulation of HMGB1
will shield cisplatin-DNA crosslinks from re-
pair and enhance cell death.
estrogen to the same population of cells. Furthermore, pound. We tried a variety of coupling methodologies in
an attempt to attach cis, cis, trans-diamminedichlorodi-release of cisplatin and unmodified estradiol can readily
be achieved by use of the platinum(IV) platform. The succinatoplatinum(IV) directly to estradiol-3-benzoate;
however, the desired compound could not be obtained.concurrent delivery of cisplatin and estrogen allows for
the selective targeting of ER() cells by conferring both Next, 17-hemisuccinate-estradiol-3-benzoate was syn-
thesized, and numerous attempts were made to coupleDNA damage and HMGB1-induced repair shielding.
Upon entering the cell, BEPn will be readily reduced by it to cis, cis, trans-diamminedichlorodihydroxyplati-
num(IV), but without success [29]. Ultimately, the firstglutathione or other intracellular agents to afford cis-
platin and two equivalents of the linker-modified estro- member of the BEPn family of estrogen-tethered plati-
num(IV) complexes, BEP1, was obtained through cou-gen [22, 24–26]. The linkers were designed to be suscep-
tible to hydrolysis by intracellular esterases because the pling of a linker-modified estrogen with cis, cis, trans-
diamminedichlorodisuccinatoplatinum(IV) (Figure 2).estrogen receptor does not recognize estrogens modi-
fied at the 17 position [27, 28]. Although the relative Cisplatin is readily oxidized by hydrogen peroxide to
produce cis, cis, trans-diamminedichlorodihydroxyplati-amounts of platinum and estradiol delivered to the cell
cannot be optimized, by varying length of the estrogen- num(IV) [23]. This trans-dihydroxyplatinum(IV) complex
can be further modified by reaction with succinic anhy-linker we can control the kinetics of estrogen hydrolysis
and release. dride to yield a trans-dicarboxylatoplatinum(IV) complex
that is amenable to additional derivatization. The prepa-Initial attempts to prepare the estrogen-tethered com-
plexes involved the synthesis of an ester-linked com- ration of the trans-dicarboxylatoplatinum(IV) complex
Figure 2. Route for the Preparation of the
BEPn Complexes
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Table 1. 1H NMR Data for Estrogen Ligands and Platinum Complexes in d6-DMSO at 25C
H1 H2 H4 H6 H17 H18 H19 H20 H21 H22 H23 Ha Hb
EL1 7.34 7.01 6.96 2.83 4.66 0.796 8.12 7.59 7.74 1.75 3.83
d, 1H d, 1H s, 1H m, 2H t, 1H s, 3H d, 2H t, 2H t, 1H bs, 2H d, 2H
EL2 7.32 7.00 6.94 2.83 4.67 0.814 8.08 7.58 7.73 1.75 3.04 2.68
d, 1H d, 1H s, 1H m, 2H t, 1H s, 3H d, 2H t, 2H t, 1H bs, 2H t, 2H m, 2H
EL3 7.33 7.00 6.95 2.83 4.65 0.813 8.09 7.59 7.73 1.70 2.83 2.42
d, 1H d, 1H s, 1H m, 2H t, 1H s, 3H d, 2H t, 2H t, 1H bs, 2H m, 2H m, 2H
EL4 7.32 7.00 6.95 2.83 4.65 0.815 8.09 7.59 7.73 1.70 2.83 2.36
d, 1H d, 1H s, 1H m, 2H t, 1H s, 3H d, 2H t, 2H t, 1H bs, 2H m, 2H m, 2H
EL5 7.32 7.00 6.93 2.82 4.62 0.798 8.08 7.58 7.72 1.70 2.78 2.31
d, 1H d, 1H s, 1H m, 2H t, 1H s, 3H d, 2H t, 2H t, 1H bs, 2H m, 2H m, 2H
BEP1 7.34 7.01 6.95 2.83 4.65 0.785 8.10 7.59 7.74 8.33 6.56 3.80
d, 2H d, 2H s, 2H m, 4H t, 2H s, 6H d, 4H t, 4H t, 2H t, 2H bs, 6H d, 4H
BEP2 7.35 7.00 6.95 2.83 4.65 0.799 8.10 7.60 7.74 7.95 6.49 3.23 2.43
d, 2H d, 2H s, 2H m, 4H t, 2H s, 6H d, 4H t, 4H t, 2H t, 2H bs, 6H t, 4H m, 4H
BEP3 7.35 7.00 6.96 2.83 4.69 0.805 8.12 7.59 7.74 7.85 6.50 3.04 2.47
d, 2H d, 2H s, 2H m, 4H t, 2H s, 6H d, 4H t, 4H t, 2H t, 2H bs, 6H t, 4H m, 4H
BEP4 7.35 7.00 6.97 2.84 4.64 0.804 8.10 7.60 7.74 7.85 6.51 3.01 2.44
d, 2H d, 2H s, 2H m, 4H t, 2H s, 6H d, 4H t, 4H t, 2H t, 2H bs, 6H t, 4H m, 4H
BEP5 7.32 6.98 6.94 2.82 4.62 0.799 8.09 7.57 7.71 7.81 6.49 2.98 2.40
d, 2H d, 2H s, 2H m, 4H t, 2H s, 6H d, 4H t, 4H t, 2H t, 2H bs, 6H t, 4H m, 4H
1H NMR data are given in ppm. See Figure 2 for an atom-labeling diagram.
presented here is a variation of a previously reported linked compounds. Formation of the amide bond is evi-
dent from the loss of the free amino NH2 proton reso-synthesis [30] that affords a similar yield, requires less
stringent conditions, and leads to a product in 15 hr nance at 1.70–1.75 ppm and the appearance of an amide
proton resonance at 7.80–8.33 ppm (H22). The 1H NMRversus 24–48 hr. The resulting cis, cis, trans-diammine-
dichlorodisuccinatoplatinum(IV) complex was charac- data provide quantitative evidence for the presence of
two estrogen moieties for every platinum center. Theterized by ESI-MS, 1H NMR, and 195Pt NMR spectros-
copy. The platinum ammine proton resonances appear integrated intensity of the methyl protons (H18) of the two
estrogen groups matches that of the platinum-ammineas a broad singlet at 6.51 ppm, a value that is consistent
with the ammine chemical shifts of other trans-dicarbox- protons (H23). In addition, there are an equal number of
amide (H22) and estrogen 17- protons (H17). The experi-ylatoplatinum(IV) complexes [22]. The succinato protons
and ammine protons integrate in a 4:3 ratio, indicating mentally determined masses for BEP1–BEP5 are in ex-
cellent agreement with the calculated values (0.003%).the presence of two succinato ligands per platinum cen-
ter. The 195Pt NMR resonance at 1226 ppm is consistent The synthetic methodology presented provides a conve-
nient method for preparing a variety of platinum(IV) com-with other known platinum(IV) carboxylates [31, 32].
The preparation of the BOC-protected aminoalkyl car- pounds for testing as anticancer drugs and has the po-
tential to target such complexes to specific tissue orboxylic acids (Ln) was based on previously published
methodology, and their 1H NMR spectra agreed with cell types.
data reported in the literature [33]. For obtaining the
series of linker-modified estrogens (ELn), estradiol-3-
benzoate was coupled with Ln by the use of diisopropyl- Overexpression of HMGB1 in MCF-7 Cells
after BEPn Treatmentcarbodiimide, followed by removal of the BOC-pro-
tecting group. The free amine provides a suitable handle The ability of compounds BEP1–BEP5 to upregulate
HMGB1 levels was investigated by immunofluorescencefor coupling to the trans-disuccinatoplatinum(IV) com-
plex. Because of their poor solubility, the EL compounds microscopy. As shown in Figure 3, 4 hr incubation with
200 nM BEP1–BEP5 induces the overexpression ofwere used without purification. Formation of the desired
linker-modified estrogens was confirmed by ESI-MS and HMGB1 in MCF-7 cells. Treatment with BEP1, BEP2,
BEP3, or BEP4 increases HMGB1 expression to a similar1H NMR spectroscopy (Table 1). A significant downfield
shift of the H17 proton resonance is observed upon for- degree as treatment with an equal amount of estradiol,
whereas BEP5 treatment induces considerably less pro-mation of the new ester linkage. Furthermore, the inte-
grated intensity of the H22 amine protons is the same as tein expression. The ability of these estrogen-tethered
platinum(IV) compounds to upregulate HMGB1 impliesthose of the H19 and H20 aromatic protons.
The amine-modified estrogens are easily coupled to that all are taken into the cell and reduced to a Pt(II)
species with concomitant release of the linker-modifiedtrans-dicarboxylatoplatinum(IV) by the use of diisopro-
pylcarbodiimide, a common peptide coupling reagent. estradiol. Moreover, hydrolysis of the linker-modified
estradiol ester group must occur to allow for interactionThe ESI-MS and 1H NMR spectroscopic data (Table 1)
confirm the presence of the desired estrogen-tethered of free-estradiol with the ER. Although hydrolysis of the
estrogenic moiety alone could result in upregulation ofplatinum(IV) complexes. Coupling of the series of amino-
modified estrogens to cis, cis, trans-diamminedichloro- HMGB1, reduction of Pt(IV) is required for DNA binding
activity [24]. From the known kinetics associated withdisuccinatoplatinum(IV) yielded the desired amide-
Chemistry & Biology
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Figure 3. Expression of HMGB1 in MCF-7 Cells as Monitored by Immunofluorescence Microscopy
MCF-7 cells were grown on cover slips and subsequently incubated with 200 nM BEPn or estradiol for 4 hr. The cell membrane was
permeabilized, and the cells were treated with anti-HMGB1 primary antibody and subsequently with a FITC-conjugated secondary antibody
to allow for HMGB1 visualization.
these processes [22, 27], it is likely that ester hydrolysis cursor that carries no steroid appendage, were nearly
identical, any difference in the ability of the derivatizedwill precede platinum(IV) reduction.
Estrogen interaction with the hormone binding do- complexes to kill the two different cell lines can be attrib-
uted to the release of estrogen and subsequent up-main induces the formation of ER homodimers, which
then associate with the estrogen response element regulation of HMGB1. The induction of HMGB1 overex-
pression after treatment with the estrogen-tethered(ERE) [34]. The exact mechanism by which estrogen
binding to the ER induces overexpression of HMGB1 is platinum(IV) complexes did not always translate to sen-
sitization of MCF-7 cells. Instead, as shown in Table 2,not known; however, the presence of HMGB1 is required
for ER interaction with the ERE [35, 36]. HMGB1 may the sensitivity of these cells to compounds BEP1–BEP5
varies with linker length. The cytotoxicities of BEP1 andfacilitate ER interaction with the ERE either by bending
the element to provide a binding site for the ER or by BEP2 were quite comparable in MCF-7 and HCC-1937
cells, whereas BEP5 was more cytotoxic to the HCC-stabilizing the distorted DNA of the ER-ERE complex
[34, 36]. The ability of the ER to bind to the ERE may 1937 cells. One possible explanation for these results
is that the elevated levels of HMGB1 produced by thesealso be affected by the intracellular levels of HMGB1 or
by the number of free HMGB1 binding sites [36]. In complexes do not lead to a significant amount of plati-
num-DNA adduct repair shielding. The cytotoxic profileaddition, HMGB1 increases the transcriptional activity
of the ER [37]. of BEP5 may be explained by the relatively low level of
HMGB1 overexpression induced upon treatment of the
MCF-7 cells. As shown in Figure 4, BEP3 is significantlySelective Cytotoxic Behavior of BEP1–BEP5
in ER() versus ER() Cells more cytotoxic in the MCF-7 cells. Based on IC50 values,
MCF-7 cells were 1.8- and 1.3-fold more sensitive to-The ability of BEP1–BEP5 to stimulate upregulation of
HMGB1 suggests that ER() cells will be more sensitive ward BEP3 and BEP4 treatment, respectively, than they
were to HCC-1937 cells. The differential toxicity towardthan ER() cells toward these compounds. The cyto-
toxic behavior of BEP1–BEP5 and cis, cis, trans- MCF-7 and HCC-1937 cells observed with BEP3 and
BEP4 suggest that these compounds can upregulate[Pt(NH3)2Cl2(succinato)2] was evaluated in human breast
cancer cell lines MCF-7 and HCC-1937, which are ER()
and ER(), respectively. Cell viability was evaluated by
Table 2. IC50 values, in M, for BEP1–BEP5both the sulforhodamine B (SRB) and colony-counting
Cytotoxicity Ratioassays. The two methods provided comparable dose
Compound MCF-7 HCC-1937 (HCC-1937:MCF-7)response curves, with the SRB assay resulting in less
variance in the results. The colony-counting method af- BEP1 3.2  0.1 3.4  0.4 1.1
BEP2 3.0  0.2 3.6  1.2 1.2forded more reliable data for BEP5, however. Because,
BEP3 2.1  0.4 3.7  0.9 1.8in a control experiment, the sensitivities of the MCF-7
BEP4 3.7  0.5 4.8  0.5 1.3and HCC-1937 cells (IC50  4.0 M) to cis, cis, trans-
BEP5 5.5  1.7 3.0  0.2 0.55
[Pt(NH3)2Cl2(succinato)2], the BEPn family synthetic pre-
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sion at such a time that repair shielding of the platinum
DNA adducts is maximized, whereas BEP1 and BEP2
induce HMGB1 overexpression but the timing is insuffi-
cient to sensitize the cells to cisplatin-DNA lesions.
Despite the sensitization of ER() cells to BEP3 treat-
ment, the degree of cytotoxicity achieved with cisplatin/
estrogen cotreatment was not attained (IC50  1.0 M).
The diminished cytotoxicity of BEP3 compared to cis-
platin/estrogen coadministration may be a conse-
quence of reduced uptake of the different pharmacoki-
netics of the estrogen-tethered platinum(IV) complex.
The concentration of estrogen delivered to the cell may
also be a factor. When cells were treated with cisplatin
and estrogen alone, 200 nM concentrations of estradiol
were used, whereas BEPn complexes deliver micromolar
concentrations of the hormone. It is also possible that
the estrogen dose administered by BEPn treatment itself
induces a degree of cell proliferation. Alternatively, the
micromolar concentration of estrogen could induce in-
creased HMGB1 overexpression, which may actually
inhibit cell death instead of leading to enhanced apopto-
sis [38]. Despite these caveats, the BEPn compounds
provide a new model for the development of platinum(IV)
complexes designed to target and treat a variety of can-
cers in a specific manner, based on known cellular path-
ways. Animal studies are in progress for further investi-
gation of the potential utility of BEP3 as an anticancer
agent.
Significance
Figure 4. Effect of BEP3 Treatment on MCF-7 and HCC-1937 Cell
Survival, as Monitored by the SRB Assay ( SD) Several novel estrogen-tethered platinum(IV) com-
Cells were treated continuously for 72–96 hr. Experiments were plexes were synthesized, evaluated for their ability to
carried out on at least three separate days with triplicate cultures
upregulate HMGB1, and screened for cytotoxicityfor each drug concentration.
against breast cancer cell lines. All BEPn complexes
induced the overexpression of HMGB1 in ER() MCF-7
HMGB1 in a manner that is kinetically competent to cells. BEP3 was nearly 2-fold more cytotoxic in ER()
shield cisplatin-DNA adducts from repair and sensitize MCF-7 cells than in ER() HCC-1937 cells. This result
the cells. It is significant that BEP3 is nearly 2-fold more suggests the possibility of using compounds of this
active in MCF-7 cells because an identical degree of class specifically to target ER() malignancies, such
differential cytoxicity was achieved by independent ad- as breast and ovarian cancers. In addition, these BEPn
ministration of cisplatin and estradiol [15]. compounds provide an example of a novel strategy—
The importance of the kinetics of HMGB1 upregulation namely, using mechanistic insights to aid in the ra-
in determining the toxicities of compounds BEP1–BEP5 tional design of new complexes—in the development
can be understood in the light of our laboratory’s previ- of platinum-containing anticancer agents. The chem-
ous work demonstrating that estrogen-induced cisplatin istry used to construct the BEPn complexes is of poten-
sensitization was only achieved when the two com- tial utility for attaching other moieties to direct plati-
pounds were coadministered [15]. In addition, sensitiza- num complexes to cancer cells and improve their
tion to carboplatin was maximized when MCF-7 cells efficacy.
were pretreated for 24 hr with hormone. These observa-
tions suggest that the kinetics of HMGB1 overexpres-
Experimental Proceduression and platinum-DNA adduct formation are critical for
achieving an optimal level of repair shielding. The rate
General Considerations
of ester hydrolysis depends upon the length of the sub- Potassium tetrachloroplatinate(II) was a gift from Engelhard. Cis-
stituent attached at the estrogen 17 position [28]. The platin and cis, cis, trans-diamminedichlorodihydroxyplatinum(IV)
were prepared as described in the literature [23, 39]. The preparationtiming of hormone interaction with the ER and subse-
of compounds L2, L3, L4, and L5 was based on previously reportedquent HMGB1 overexpression are therefore also ex-
methodology [33]. All chemicals and solvents were purchased frompected to depend upon the length of the ester linker
commercial sources unless specified otherwise. 1H and 195Pt NMRchain. The inability of BEP5 to induce significant HMGB1
spectra were recorded on either a Varian 300 MHz or a 500 MHz
upregulation after a 4 hr treatment may be a conse- spectrometer at the MIT Department of Chemistry Instrumentation
quence of the kinetics of ester hydrolysis. It is possible Facility (DCIF). High-resolution mass spectral analysis was carried
out at the MIT DCIF.that compound BEP3 stimulates HMGB1 overexpres-
Chemistry & Biology
562
Synthesis of cis, cis, trans- Synthesis of 17-(3-Aminopropionate)-Estradiol-
3-Benzoate (EL2)Diamminedichlorodisuccinatoplatinum(IV) (1)
Succinic anhydride (4.1 g, 41 mmol) and cis, cis, trans-diammine- A solution of L2 (2.1 g, 11 mmol) and 4-DMAP (1.3 g, 11 mmol) was
prepared in 100 ml of DMF. Diisopropylcarbodiimide (1.7 mL, 11dichlorodihydroxyplatinum(IV) (3.3 g, 10 mmol) were dissolved in
5 ml of DMSO. The solution was heated to 70C for 15 hr with mmol) was added, and the solution was stirred for 10 min. Estradiol-
3-benzoate (2.6 g, 6.9 mmol) was added, and the reaction wasconstant stirring, cooled to room temperature, and filtered. The
DMSO solvent was removed from the filtrate by lyophilization to yield allowed to stir for 7 hr. The solution was filtered, diluted with water,
and extracted with ether. The organic fractions were combined anda yellow solid. Recrystallization from acetone at 20C afforded a
pale yellow solid (3.7 g, 6.9 mmol, 69% yield). 1H NMR (d6-acetone, evaporated to dryness to yield a pink residue. The residue was
dissolved in 800 ml of methylene chloride; 120 ml TFA was added,300 MHz): 	 2.45 (m, 4H, CH2), 2.53 (m, 4H, CH2), 6.511 (broad singlet,
6H, NH3). 195Pt NMR (500 MHz): 	 1226.531. ERMS (ESI) calculated and the solution was stirred for 2 hr. The methylene chloride was
evaporated to yield a pink oil, which was dissolved in H2O and hadfor [M  H] 534.0004 amu, found 534.0001 amu.
its pH adjusted to 10 with ammonium hydroxide. A white solid began
to precipitate, and the slurry was stirred for an additional hour.Synthesis of 3-tert-Butoxycarbonylaminopropionic Acid (L2)
Filtering the solution caused a white solid (approximately 3 g ofTriethylamine (6.2 ml, 45 mmol) was added to a solution of 3-amino-
crude material) to collect. 1H NMR (d6-DMSO, 300 MHz): 	 8.08 (d,propionic acid (2.67 g, 30.0 mmol) in 50% aqueous dioxane (30 ml).
2H, ArH), 7.73 (t, 1H, ArH), 7.58 (t, 2H, ArH), 7.32 (d, 1H, ArH), 7.00BOC-ON (8.15 g, 33.1 mmol) was added, and the reaction was stirred
(d, 1H, ArH), 6.94 (s, 1H, ArH), 4.67 (t, 1H, CH), 3.04 (t, 2H, CH2), 2.83for 3 hr at room temperature. The reaction solution was diluted with
(m, 2H, CH), 2.68 (m, 2H, CH2), 2.30–1.20 (m, 13H, CH/CH2), 1.70 (bs,H2O (40 ml) and ethyl acetate (60 ml). The aqueous layer was isolated,
2H, NH2), 0.814 (s, 3H, CH3). HRMS (ESI) calculated for [M  H]washed with ethyl acetate, and acidified with a 5% citric-acid solu-
448.2482 amu, found 448.2481.tion. The aqueous layer was subsequently extracted with ethyl ace-
tate. The organic fractions were combined and evaporated to yield
Synthesis of 17-(4-Aminobutanoate)-L2 as a cream solid (3.6 g, 19 mmol, 63% yield). 1H NMR (d6-DMSO,
Estradiol-3-Benzoate (EL3)300 MHz): 	 1.35 (s, 9H, CH3), 2.33 (t, 2H, CH2), 3.11 (q, 2H, CH2),
This compound was prepared as described for EL2 with L3 (1.8 g,6.67 (t, 1H, NH). HRMS (ESI) calculated for [M  H] 188.0928 amu,
8.9 mmol), 4-DMAP (1.1 g, 9.1 mmol), diisopropylcarbodiimide (1.4found 188.0922 amu.
ml, 8.9 mmol), and estradiol-3-benzoate (2.2 g, 5.7 mmol). For re-
moval of the BOC-protecting group, 700 ml methylene chloride andSynthesis of 4-tert-Butoxycarbonylaminobutyric Acid (L3)
100 ml TFA were stirred into the solution. A white solid was isolatedThis compound was prepared as described for L2 from stirring
(2.56 g crude) and used without purification. 1H NMR (d6-DMSO, 3004-aminobutyric acid (3.9 g, 38 mmol) in 50% aqueous dioxane with
MHz): 	 8.09 (d, 2H, ArH), 7.73 (t, 1H, ArH), 7.59 (t, 2H, ArH), 7.33 (d,triethylamine (8.0 ml, 57 mmol) and BOC-ON (10.4 g, 42 mmol). A
1H, ArH), 7.00 (d, 1H, ArH), 6.95 (s, 1H, ArH), 4.65 (t, 1H, CH), 2.83 (m,yellow oil that solidified upon addition of hexanes was obtained,
4H, CH2), 2.42 (m, 2H, CH2), 2.40–2.00 (m, 3H, CH2), 1.81 (m, 4H, CH2),and cooling to –20C yielded a cream solid (4.0 g, 19 mmol, 52%
1.70 (bs, 2H, NH2), 1.60–1.20 (m, 8H, CH), 0.813 (s, 3H, CH3). HRMSyield). 1H NMR (d6-DMSO, 300 MHz): 	 1.36 (s, 9H, CH3), 1.57 (m, (ESI) calculated for [M  H] 462.2639 amu, found 462.2622 amu.2H, CH2), 2.17 (t, 2H, CH2), 2.90 (m, 2H, CH2), 6.80 (t, 1H, NH). HRMS
(ESI) calculated for [M  H] 202.1085 amu, found 202.1075 amu.
Synthesis of 17-(5-Aminopentanoate)-
Estradiol-3-Benzoate (EL4)
Synthesis of 5-tert-Butoxycarbonylaminopentanoic Acid (L4) This compound was prepared as described for EL2 with L4 (1.3 g,
This compound was prepared as described for L2 from 5-aminopen- 6.6 mmol), 4-DMAP (0.82 g, 6.7 mmol), diisopropylcarbodiimide (1.0
tanoic acid (3.4 g, 29 mmol), triethylamine (6.0 ml, 43 mmol), and ml, 6.4 mmol), and estradiol-3-benzoate (1.6 g, 4.1 mmol). For depro-
BOC-ON (7.9 g, 32 mmol). A cream solid (3.1 g, 14 mmol) was tection of the amine, 480 ml of methylene chloride and 72 ml of TFA
isolated in 49% yield. 1H NMR (d6-DMSO, 300 MHz): 	 1.36 (s, 9H, were stirred into the solution. A white solid was isolated (1.89 g
CH3), 1.43 (m, 4H, 2CH2), 2.17 (t, 2H, CH2), 2.88 (m, 2H, CH2), 6.73 crude). 1H NMR (d6-DMSO, 300 MHz): 	 8.09 (d, 2H, ArH), 7.73 (t,
(t, 1H, NH). HRMS (ESI) calculated for [MH] 216.1241 amu, found 1H, ArH), 7.59 (t, 2H, ArH), 7.32 (d, 1H, ArH), 7.00 (d, 1H, ArH), 6.95
216.1244 amu. (s, 1H, ArH), 4.65 (t, 1H, CH), 2.83 (m, 4H, CH2), 2.36 (m, 2H, CH2),
2.30–2.00 (m, 3H, CH), 1.90–1.72 (m, 4H, CH) 1.70 (bs, 2H, NH2), 1.57
Synthesis of 6-tert-Butoxycarbonylaminohexanoic Acid (L5) (m, 4H, CH2), 1.42–1.20 (m, 6H, CH), 0.815 (s, 3H, CH3). HRMS (ESI)
This compound was prepared as described for L2 from 6-aminohex- calculated for [M  H] 476.2795 amu, found 476.2800 amu.
anoic acid (3.5 g, 27 mmol), triethylamine (5.5 ml, 40 mmol), and
BOC-ON (7.5 g, 30 mmol). A pale yellow solid (3.0 g, 13 mmol) was Synthesis of 17-(6-Aminohexanoate)-
isolated in 48% yield. 1H NMR (d6-DMSO, 300 MHz): 	 1.20 (m, 2H, Estradiol-3-Benzoate (EL5)
CH2), 1.30 (m, 2H, CH2), 1.36 (s, 9H, CH3), 1.46 (m, 2H, CH2), 2.16 (t, This compound was prepared as described for EL2 with L5 (1.1 g,
2H, CH2), 2.87 (m, 2H, CH2), 6.74 (t, 1H, NH). HRMS (ESI) calculated 4.6 mmol), 4-DMAP (0.58 g, 4.8 mmol), diisopropylcarbodiimide (730
for [M  H] 230.1398 amu, found 230.1395 amu. l, 4.7 mmol), and estradiol-3-benzoate (0.51 g, 1.4 mmol). For re-
moval of the BOC group, a solution of TFA (25 ml) in methylene
chloride (240 ml) was added. A white solid was isolated by filtrationSynthesis of 17-(Aminoacetoxy)-Estradiol-3-Benzoate (EL1)
(0.6 g crude). 1H NMR (d6-DMSO, 300 MHz): 	 8.08 (d, 2H, ArH), 7.72Diisopropylcarbodiimide (3.7 ml, 24 mmol) was added to a solution
(t, 1H, ArH), 7.58 (t, 2H, ArH), 7.32 (d, 1H, ArH), 7.00 (d, 1H, ArH),of N-tert-butoxycarbonylglycine (4.2 g, 24 mmol) and 4-dimethylami-
6.93 (s, 1H, ArH), 4.62 (t, 1H, CH), 2.82 (m, 2H, CH2), 2.78–2.77 (m,nopyridine (4-DMAP; 3.0 g, 24 mmol) in THF (200 mL). The solution
4H, CH2), 2.31 (m, 2H, CH2), 2.23–1.72 (m, 6H, CH), 1.70 (bs, 2H,was stirred for 10 min before the addition of estradiol-3-benzoate
NH2), 1.57–1.20 (m, 10H, CH/CH2), 0.798 (s, 3H, CH3). HRMS (ESI)(5.0 g, 13 mmol). After being stirred overnight, the solution was
calculated for [M  H] 490.2952 amu, found 490.2954 amu.filtered, and the solvent was removed by rotary evaporation. The
solid residue was dissolved in a 1 M HCl/dioxane solution (265 ml)
and stirred for an additional 6 hr. After evaporation of dioxane, the Synthesis of cis, cis, trans-Diamminedichloro-bis-
(17-(N-Carbonylmethylsuccinato)-Estradiol-3-residue was suspended in 100 ml H2O, and the pH was adjusted to
10 with ammonium hydroxide. The solution was stirred for several Benzoate)platinum(IV) (BEP1)
Diisopropylcarbodiimide (0.57 ml, 3.7 mmol) was added to a solutionhours and filtered to yield a white solid (4.3 g, 9.9 mmol, 75%). 1H
NMR (d6-DMSO, 300 MHz): 	 8.12 (d, 2H, ArH), 7.74 (t, 1H, ArH), 7.59 of 1 (0.81 g, 1.5 mmol) and 4-DMAP (0.48 g, 3.9 mmol) in DMF (100
ml). The solution was allowed to stir for 10 min at room temperature(t, 2H, ArH), 7.34 (d, 1H, ArH), 7.01 (d, 1H, ArH), 6.96 (s, 1H, ArH),
4.66 (t, 1H, CH), 3.83 (d, 1H, CH), 2.83 (m, 2H, CH), 1.75 (bs, 2H, before the addition of EL1 (1.6 g, 3.7 mmol). The solution was stirred
for 15 hr at room temperature and then filtered, and the filtrate wasNH2); 2.3–1.2 (m, 13H, CH2), 0.796 (s, 3H, CH3). HRMS (ESI) calculated
for [M  H] 434.2326 amu, found 434.2319 amu. diluted with 200 ml of ether. Cooling the resultant solution at 20C
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for 10 hr facilitated precipitation. The crude product was filtered, (ATCC) containing 10% FBS and 1
 antibiotic/antimycotic solution.
All cells were incubated at 37C under a 5% CO2 atmosphere.triturated with ethanol (30 ml), and centrifuged (five times). The tan
solid was then triturated with boiling water (10 ml) five times and
centrifuged to yield a pale yellow solid (0.72 g, 0.53 mmol, 35% Overexpression of HMGB1 Induced by BEPn Complexes
yield). 1H NMR (d6-DMSO, 300 MHz): 	 8.33 (t, 2H, NH), 8.10 (d, 4H, MCF-7 cells were grown to 70% confluence on 12 mm glass cover
ArH), 7.74 (t, 2H, ArH), 7.59 (t, 4H, ArH), 7.34 (d, 2H, ArH), 7.01 (d, slips in 24-well plates. The cells were treated with either estrogen
2H, ArH), 6.95 (s, 2H, ArH), 6.56 (bs, 6H, NH3), 4.65 (t, 2H, CH), 3.80 or BEPn and incubated for 4 hr. The cells were then permeabilized
(d, 4H, CH2), 2.83 (m, 4H, CH2), 2.60–1.20 (m, 34H, CH/CH2), 0.785 with 25% acetic acid in methanol for 10 min at room temperature,
(s, 6H, CH3). HRMS calculated for [M  H] 1364.4299 amu, found washed with PBS, and incubated with a 1:100 dilution of anti-
1364.4253 amu. HMGB1 polyclonal antibody (PharMingen) for 1 hr at 37C. The cells
were subsequently incubated with a 1:200 dilution of goat anti-
Synthesis of cis, cis, trans-Diamminedichloro-bis- rabbit IgG conjugated to FITC (Biosource International) for 1 hr at
(17-(N-(2-Carboxy-Ethyl)-Succinato)-Estradiol- 37C. The cover slips were then placed on microscope slides, fixed
3-Benzoate)platinum(IV) (BEP2) with gelvatol, and incubated at 4C for 12 hr. HMGB1 levels were
This compound was prepared as described for BEP1 with 1 (0.37 then visualized under a fluorescent-light microscope (Nikon)
g, 0.69 mmol), 4-DMAP (0.36 g, 2.9 mmol), diisopropylcarbodiimide equipped with a digital camera (Diagnostic Instruments).
(430 l, 2.7 mmol), and EL2 (1.2 g, 2.8 mmol). Crude BEP2 was
purified as described for BEP1 to yield a pale yellow solid (0.13 g,
Cytotoxic Profile of BEPn0.093 mmol, 14% yield). 1H NMR (d6-DMSO, 300 MHz): 	 8.10 (d, The cytotoxicities of the BEPn compounds were evaluated by two4H, ArH), 7.95 (t, 2H, NH), 7.74 (t, 2H, ArH) 7.60 (t, 4H, ArH), 7.35 (d,
methodologies, SRB and colony-counting assays. For the SRB
2H, ArH), 7.00 (d, 2H, ArH), 6.95 (s, 2H, ArH), 6.49 (bs, 6H, NH3), 4.65 assay, MCF-7 and HCC-1937 cells were seeded onto 96-well plates
(t, 2H, CH), 3.23 (t, 4H, CH2), 2.83 (m, 4H, CH), 2.43 (m, 4H, CH2), at a density of 1000 cells per well and allowed to grow for 24 hr.
2.43–1.20 (m, 34H, CH/CH2), 0.799 (s, 6H, CH3). HRMS (ESI) calcu- Cells were treated with compounds BEP1–BEP5 at the following
lated for [M  H] 1391.4591 amu, found 1391.4562 amu.
concentrations: 1, 2, 3, 4, 5, 6, 8, and 10 M. The 96-well plates were
covered with Breathe-Easy gas-permeable membranes (Diversified
Synthesis of cis, cis, trans-Diamminedichloro-bis- Biotech), and the cells incubated at 37C for 96 hr. After the incuba-
(17-(N-(3-Carboxy-Propyl)-Succinato)-Estradiol- tion period, the cells were fixed by the addition of 25 l of 50% TCA
3-Benzoate)platinum(IV) (BEP3) and subsequent incubation at 4C for 30 min. The viable cells were
This compound was prepared as described for BEP1 with 1 (0.65 g, then stained by the addition of 100 l of sulforhodamine B in 0.1%
1.2 mmol), 4-DMAP (0.61 g, 5.0 mmol), diisopropylcarbodiimide (760 acetic acid followed by incubation for 30 min at room temperature.
l, 4.9 mmol), and EL3 (2.3 g, 5.0 mmol). The crude material was The cells were washed with 1% acetic acid and allowed to dry
purified as described for BEP1 to yield a pale yellow solid (0.12 g, overnight. The SRB was solubilized by the addition of 100 l of 10
0.084 mmol, 7.0% yield). 1H NMR (d6-DMSO, 300 MHz): 	 8.12 (d, mM Tris (pH 10.5) and subsequent shaking for 5 min. The number
4H, ArH), 7.85 (t, 2H, NH), 7.74 (t, 2H, ArH) 7.59 (t, 4H, ArH), 7.35 (d, of viable cells was then quantified by measurement of the ab-
2H, ArH), 7.00 (d, 2H, ArH), 6.96 (s, 2H, ArH), 6.50 (bs, 6H, NH3), 4.69 sorbance at 492 nm.
(t, 2H, CH), 3.26 (t, 4H, CH2), 3.04 (t, 4H, CH2), 2.83 (m, 4H, CH2), 2.47 For the colony-counting assay, MCF-7 and HCC-1937 cells were
(m, 4H, CH2), 2.40–1.20 (m, 34H, CH2), 0.805 (s, 6H, CH3). HRMS (ESI) seeded onto 6-well plates at a density of 1000 cells per well in 2 ml
calculated for [M  H] 1419.4904, found 1419.4890 amu. media and allowed to grow for 24 hr. Cells were then treated for 72
hr with the BEPn complexes at the following concentrations: 0, 2,
Synthesis of cis, cis, trans-Diamminedichloro-bis- 4 6, 8, and 10 M. After 72 hr, cells were washed with PBS, and
(17-(N-(4-Carboxybutyl)-Succinato)-Estradiol- fresh medium was added. Staining the cells with a 1% methylene
3-Benzoate)platinum(IV) (BEP4) blue/50% ethanol (vol/vol) solution after 7 days allowed the colonies
This compound was prepared as described for BEP1 with 1 (0.22 to be counted.
g, 0.40 mmol), 4-DMAP (0.15 g, 1.2 mmol), diisopropylcarbodiimide
(189 l, 1.2 mmol), and EL4 (0.62 g, 1.3 mmol). The crude material
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